BeOne wins mantle cell lymphoma approval, opening new therapy class

FDA Clears BeOne's Beqalzi for Relapsed/Refractory Mantle Cell Lymphoma

The FDA has granted accelerated approval to BeOne Medicines’ BCL2 inhibitor, sonrotoclax (brand name Beqalzi), for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL). This approval is specifically for patients who have undergone at least two prior lines of systemic therapy, including a BTK inhibitor. Beqalzi is the first BCL2 inhibitor cleared for this indication and represents BeOne's third commercial product. The decision was supported by Phase 1/2 data from a single-arm, open-label study of 125 R/R MCL patients, showing a 52% overall response rate, a 16% complete response rate, and a median duration of response of 15.8 months. A confirmatory Phase 3 study, CELESTIAL-RRMCL, is underway. Analysts forecast $300-$400 million in sales for this indication.

• Beqalzi's approval marks a significant advancement as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma, addressing a critical unmet need for patients who have progressed after at least two prior systemic therapies, including a BTK inhibitor. The FDA's accelerated pathway approval underscores the urgency for new treatments in this challenging patient population, with a confirmatory Phase 3 study (CELESTIAL-RRMCL) required to verify long-term clinical benefits. This milestone solidifies Beqalzi's position as a novel therapeutic option within the R/R MCL landscape.
• The regulatory decision was primarily driven by robust efficacy data from a Phase 1/2 single-arm, open-label study involving 125 patients with R/R MCL. The trial demonstrated a compelling overall response rate (ORR) of 52%, with a notable 16% of patients achieving a complete response (CR). Furthermore, the median duration of response (DoR) was reported at 15.8 months, indicating sustained clinical benefit for a significant portion of responders. These results highlight Beqalzi's potential to induce meaningful and durable responses in a heavily pre-treated patient group.
• While the initial market for R/R MCL is considered relatively small, with Truist Securities forecasting $300-$400 million in sales for this indication, BeOne is strategically positioning Beqalzi for broader impact. The company is actively investigating Beqalzi in combination with Beqvez for chronic lymphocytic leukemia (CLL), a market with substantially higher peak sales potential, projected to exceed $3.4 billion. This broader development strategy suggests Beqalzi could become a more significant asset for BeOne, extending its therapeutic reach beyond its initial MCL approval.

Addressing Unmet Needs in Relapsed/Refractory MCL

Over the past three years, mantle cell lymphoma (MCL) research has intensified focus on addressing critical gaps in treatment outcomes for specific high-risk populations. Despite therapeutic advances including CAR-T cell therapy and novel targeted agents, significant unmet medical needs persist, particularly in patients with aggressive disease features and those experiencing treatment failure.

• TP53-mutated MCL patients represent the most critical unmet need, as TP53 mutations serve as predictors of early disease progression and poor prognosis, with optimal treatment strategies remaining unclear despite targeted therapy approaches showing promise

• Relapsed/refractory disease after BTK inhibitor failure constitutes a major challenge, as patients often require multiple treatment lines and face poor prognosis, particularly those failing covalent BTK inhibitor therapy where resistance mechanisms and severe side effects frequently result in treatment failure

• Elderly patients (>65 years) lack standardized treatment options, with 48% presenting high-risk disease based on MIPI-c scores and 36.4% having ECOG performance scores of 2-3 at diagnosis, while the disease remains incurable with current modalities in this population

• High-risk genetic and morphologic features including blastoid variant morphology, Ki-67 >30%, and specific chromosomal deletions at 17p13.3, 13q14.2, and 19p13.3 identify patients requiring targeted therapeutic approaches

• Post-CAR-T therapy failures represent an emerging unmet need, as patients who experience primary resistance or secondary recurrence after CAR-T cell treatment face limited therapeutic options, with allogeneic transplantation potentially playing an important salvage role

• Treatment sequencing optimization remains unclear for contemporary management strategies incorporating bispecific antibodies and CAR-T therapy, particularly determining optimal positioning of these novel cellular therapies in treatment algorithms

Phase 1/2 Data Supporting Beqalzi's Accelerated Approval

Recent clinical studies in mantle cell lymphoma have demonstrated promising outcomes across both novel targeted therapies and established combination regimens. The M20-075 study evaluated ibrutinib plus venetoclax in Japanese patients with relapsed/refractory MCL, showing remarkable efficacy with an 83% overall response rate (all complete responses) after a median follow-up of 37.2 months. Notably, all six patients with detectable minimal residual disease at baseline achieved undetectable MRD status, and median duration of response, progression-free survival, and overall survival were not reached. The safety profile was manageable, with neutropenia (46%) and leukopenia (23%) representing the most frequent Grade ≥3 treatment-emergent adverse events, and only one discontinuation due to an unrelated squamous cell carcinoma.

The FIL_V-RBAC study introduced a novel risk-stratified approach for treatment-naive elderly MCL patients, utilizing RBAC (rituximab, bendamustine, cytarabine) induction followed by venetoclax consolidation and maintenance in high-risk patients. Among 54 high-risk patients with features such as TP53 mutations, 17p deletions, Ki67 ≥30%, or blastoid morphology, the 2-year progression-free survival was 60% with a median PFS of 37 months. Safety during venetoclax phases showed Grade ≥3 neutropenia in 28% during consolidation and 19% during maintenance, with one treatment-related death from tumor lysis syndrome. The CHESS trial evaluated zanubrutinib-rituximab followed by shortened chemoimmunotherapy (R-DHAOx) in frontline MCL, achieving complete response rates of 88% after Part A and 86% after Part B completion in 42 patients.

CAR-T cell therapy showed significant promise in the relmacabtagene autoleucel study, where Chinese patients with heavily pretreated relapsed/refractory MCL received a single infusion of 100 × 10⁶ CAR-positive T cells. The therapy achieved a 71.19% objective response rate at 3 months with a 59.32% complete response rate, demonstrating durable responses with median duration of response, progression-free survival, and overall survival of 18.1, 15.5, and 19.5 months respectively. While high-grade hematologic toxicities were common (neutropenia 76.3%, leukopenia 69.5%), severe cytokine release syndrome and neurotoxicity occurred in only 6.8% of patients each, with all cases resolving completely and no fatal events reported.

A New BCL2 Inhibitor Reshapes R/R MCL Treatment

The recent accelerated approval of sonrotoclax for relapsed or refractory mantle cell lymphoma (R/R MCL) marks a pivotal moment for patients facing limited options after progression on Bruton's tyrosine kinase (BTK) inhibitors. This decision by the FDA validates BCL2 inhibition as a critical therapeutic strategy in a disease where patients often experience relapse and require multiple lines of treatment. For BeOne Medicines, this represents a significant expansion of its oncology footprint, introducing its third commercial product into a high-need area with considerable market potential.

This approval is particularly impactful because it provides a formally approved, targeted oral therapy for a patient population that has exhausted prior BTK inhibitor treatments. The reported 52% overall response rate and a median duration of response of 15.8 months from the supporting Phase 1/2 data offer a tangible benefit for patients with a historically poor prognosis. This new option will undoubtedly influence the evolving treatment landscape for R/R MCL, offering clinicians a clearer pathway for patients who have progressed on established targeted therapies.

However, several considerations are paramount:

• Confirmatory Data: As an accelerated approval, the continued availability of sonrotoclax hinges on the successful completion and positive outcomes of the ongoing Phase 3 CELESTIAL-RRMCL study. The full scope of its long-term efficacy and safety profile will be critical.

• Resistance Mechanisms: Experience with other BCL2 inhibitors suggests that resistance, often driven by the upregulation of anti-apoptotic proteins like MCL-1 and BCL-xL, can emerge. Understanding and mitigating these mechanisms will be key to maximizing sonrotoclax's long-term utility.

• Safety Profile: While generally well-tolerated, BCL2 inhibitors require careful management, particularly regarding potential toxicities such as tumor lysis syndrome. The safety profile in a heavily pretreated, often frail, R/R MCL population will require close monitoring, especially if combination strategies are explored in the future.

Ultimately, sonrotoclax's entry into the R/R MCL armamentarium underscores the shift towards targeted, chemotherapy-free regimens. Future research will likely focus on optimizing its use, potentially in combination with other agents, and personalizing treatment based on individual patient genomic profiles to overcome resistance and improve durable remission rates in this challenging malignancy.